0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Immune-mediated Necrotizing Myopathy Treatment Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-6F13861
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Immune mediated Necrotizing Myopathy Treatment Market Research Report 2023
BUY CHAPTERS

Global Immune-mediated Necrotizing Myopathy Treatment Market Research Report 2025

Code: QYRE-Auto-6F13861
Report
May 2025
Pages:73
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Immune-mediated Necrotizing Myopathy Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Immune-mediated Necrotizing Myopathy Treatment Market

Immune-mediated Necrotizing Myopathy Treatment Market

The global market for Immune-mediated Necrotizing Myopathy Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Immune-mediated necrotizing myopathy (IMNM) is a rare autoimmune muscle disease characterized by muscle inflammation and weakness. Treatment for immune-mediated necrotizing myopathy typically involves immunosuppressive therapies aimed at modulating or suppressing the immune response to reduce muscle inflammation and prevent further damage.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Immune-mediated Necrotizing Myopathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune-mediated Necrotizing Myopathy Treatment.
The Immune-mediated Necrotizing Myopathy Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immune-mediated Necrotizing Myopathy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immune-mediated Necrotizing Myopathy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Immune-mediated Necrotizing Myopathy Treatment Market Report

Report Metric Details
Report Name Immune-mediated Necrotizing Myopathy Treatment Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Immune-mediated Necrotizing Myopathy Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Immune-mediated Necrotizing Myopathy Treatment Market report?

Ans: The main players in the Immune-mediated Necrotizing Myopathy Treatment Market are GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries, Novartis AG

What are the Application segmentation covered in the Immune-mediated Necrotizing Myopathy Treatment Market report?

Ans: The Applications covered in the Immune-mediated Necrotizing Myopathy Treatment Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Immune-mediated Necrotizing Myopathy Treatment Market report?

Ans: The Types covered in the Immune-mediated Necrotizing Myopathy Treatment Market report are Steroids, Immunosuppressant, Others

Recommended Reports

Autoimmune Disease Markets

Muscle Disease Treatment

Neuromuscular & Rare Disorders

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Steroids
1.2.3 Immunosuppressant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Perspective (2020-2031)
2.2 Global Immune-mediated Necrotizing Myopathy Treatment Growth Trends by Region
2.2.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Immune-mediated Necrotizing Myopathy Treatment Historic Market Size by Region (2020-2025)
2.2.3 Immune-mediated Necrotizing Myopathy Treatment Forecasted Market Size by Region (2026-2031)
2.3 Immune-mediated Necrotizing Myopathy Treatment Market Dynamics
2.3.1 Immune-mediated Necrotizing Myopathy Treatment Industry Trends
2.3.2 Immune-mediated Necrotizing Myopathy Treatment Market Drivers
2.3.3 Immune-mediated Necrotizing Myopathy Treatment Market Challenges
2.3.4 Immune-mediated Necrotizing Myopathy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immune-mediated Necrotizing Myopathy Treatment Players by Revenue
3.1.1 Global Top Immune-mediated Necrotizing Myopathy Treatment Players by Revenue (2020-2025)
3.1.2 Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Immune-mediated Necrotizing Myopathy Treatment Revenue
3.4 Global Immune-mediated Necrotizing Myopathy Treatment Market Concentration Ratio
3.4.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune-mediated Necrotizing Myopathy Treatment Revenue in 2024
3.5 Global Key Players of Immune-mediated Necrotizing Myopathy Treatment Head office and Area Served
3.6 Global Key Players of Immune-mediated Necrotizing Myopathy Treatment, Product and Application
3.7 Global Key Players of Immune-mediated Necrotizing Myopathy Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Immune-mediated Necrotizing Myopathy Treatment Breakdown Data by Type
4.1 Global Immune-mediated Necrotizing Myopathy Treatment Historic Market Size by Type (2020-2025)
4.2 Global Immune-mediated Necrotizing Myopathy Treatment Forecasted Market Size by Type (2026-2031)
5 Immune-mediated Necrotizing Myopathy Treatment Breakdown Data by Application
5.1 Global Immune-mediated Necrotizing Myopathy Treatment Historic Market Size by Application (2020-2025)
5.2 Global Immune-mediated Necrotizing Myopathy Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Immune-mediated Necrotizing Myopathy Treatment Market Size (2020-2031)
6.2 North America Immune-mediated Necrotizing Myopathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025)
6.4 North America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size (2020-2031)
7.2 Europe Immune-mediated Necrotizing Myopathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025)
7.4 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size (2020-2031)
8.2 Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size (2020-2031)
9.2 Latin America Immune-mediated Necrotizing Myopathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025)
9.4 Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size (2020-2031)
10.2 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Details
11.1.2 GlaxoSmithKline plc Business Overview
11.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Introduction
11.1.4 GlaxoSmithKline plc Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.1.5 GlaxoSmithKline plc Recent Development
11.2 Dr. Reddy's Laboratories
11.2.1 Dr. Reddy's Laboratories Company Details
11.2.2 Dr. Reddy's Laboratories Business Overview
11.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Introduction
11.2.4 Dr. Reddy's Laboratories Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.2.5 Dr. Reddy's Laboratories Recent Development
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Details
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Introduction
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Details
11.4.2 Hetero Drugs Limited Business Overview
11.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Introduction
11.4.4 Hetero Drugs Limited Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.4.5 Hetero Drugs Limited Recent Development
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Details
11.5.2 AbbVie Inc. Business Overview
11.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Introduction
11.5.4 AbbVie Inc. Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.5.5 AbbVie Inc. Recent Development
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Details
11.6.2 Teva Pharmaceutical Industries Business Overview
11.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Introduction
11.6.4 Teva Pharmaceutical Industries Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.6.5 Teva Pharmaceutical Industries Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Introduction
11.7.4 Novartis AG Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
11.7.5 Novartis AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Steroids
 Table 3. Key Players of Immunosuppressant
 Table 4. Key Players of Others
 Table 5. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Region (2020-2025)
 Table 9. Global Immune-mediated Necrotizing Myopathy Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Region (2026-2031)
 Table 11. Immune-mediated Necrotizing Myopathy Treatment Market Trends
 Table 12. Immune-mediated Necrotizing Myopathy Treatment Market Drivers
 Table 13. Immune-mediated Necrotizing Myopathy Treatment Market Challenges
 Table 14. Immune-mediated Necrotizing Myopathy Treatment Market Restraints
 Table 15. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Players (2020-2025)
 Table 17. Global Top Immune-mediated Necrotizing Myopathy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune-mediated Necrotizing Myopathy Treatment as of 2024)
 Table 18. Ranking of Global Top Immune-mediated Necrotizing Myopathy Treatment Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Immune-mediated Necrotizing Myopathy Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Immune-mediated Necrotizing Myopathy Treatment, Headquarters and Area Served
 Table 21. Global Key Players of Immune-mediated Necrotizing Myopathy Treatment, Product and Application
 Table 22. Global Key Players of Immune-mediated Necrotizing Myopathy Treatment, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Type (2020-2025)
 Table 26. Global Immune-mediated Necrotizing Myopathy Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Type (2026-2031)
 Table 28. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Application (2020-2025)
 Table 30. Global Immune-mediated Necrotizing Myopathy Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Application (2026-2031)
 Table 32. North America Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 47. GlaxoSmithKline plc Company Details
 Table 48. GlaxoSmithKline plc Business Overview
 Table 49. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product
 Table 50. GlaxoSmithKline plc Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 51. GlaxoSmithKline plc Recent Development
 Table 52. Dr. Reddy's Laboratories Company Details
 Table 53. Dr. Reddy's Laboratories Business Overview
 Table 54. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product
 Table 55. Dr. Reddy's Laboratories Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 56. Dr. Reddy's Laboratories Recent Development
 Table 57. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Details
 Table 58. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
 Table 59. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product
 Table 60. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 61. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
 Table 62. Hetero Drugs Limited Company Details
 Table 63. Hetero Drugs Limited Business Overview
 Table 64. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product
 Table 65. Hetero Drugs Limited Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 66. Hetero Drugs Limited Recent Development
 Table 67. AbbVie Inc. Company Details
 Table 68. AbbVie Inc. Business Overview
 Table 69. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product
 Table 70. AbbVie Inc. Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 71. AbbVie Inc. Recent Development
 Table 72. Teva Pharmaceutical Industries Company Details
 Table 73. Teva Pharmaceutical Industries Business Overview
 Table 74. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product
 Table 75. Teva Pharmaceutical Industries Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 76. Teva Pharmaceutical Industries Recent Development
 Table 77. Novartis AG Company Details
 Table 78. Novartis AG Business Overview
 Table 79. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product
 Table 80. Novartis AG Revenue in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025) & (US$ Million)
 Table 81. Novartis AG Recent Development
 Table 82. Research Programs/Design for This Report
 Table 83. Key Data Information from Secondary Sources
 Table 84. Key Data Information from Primary Sources
 Table 85. Authors List of This Report


List of Figures
 Figure 1. Immune-mediated Necrotizing Myopathy Treatment Picture
 Figure 2. Global Immune-mediated Necrotizing Myopathy Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Type: 2024 VS 2031
 Figure 4. Steroids Features
 Figure 5. Immunosuppressant Features
 Figure 6. Others Features
 Figure 7. Global Immune-mediated Necrotizing Myopathy Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Application: 2024 VS 2031
 Figure 9. Hospital Case Studies
 Figure 10. Clinic Case Studies
 Figure 11. Others Case Studies
 Figure 12. Immune-mediated Necrotizing Myopathy Treatment Report Years Considered
 Figure 13. Global Immune-mediated Necrotizing Myopathy Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Immune-mediated Necrotizing Myopathy Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Region: 2024 VS 2031
 Figure 16. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Players in 2024
 Figure 17. Global Top Immune-mediated Necrotizing Myopathy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune-mediated Necrotizing Myopathy Treatment as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Immune-mediated Necrotizing Myopathy Treatment Revenue in 2024
 Figure 19. North America Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Immune-mediated Necrotizing Myopathy Treatment Market Share by Country (2020-2031)
 Figure 21. United States Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Immune-mediated Necrotizing Myopathy Treatment Market Share by Country (2020-2031)
 Figure 25. Germany Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Immune-mediated Necrotizing Myopathy Treatment Market Share by Region (2020-2031)
 Figure 33. China Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Immune-mediated Necrotizing Myopathy Treatment Market Share by Country (2020-2031)
 Figure 41. Mexico Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Market Share by Country (2020-2031)
 Figure 45. Turkey Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Immune-mediated Necrotizing Myopathy Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. GlaxoSmithKline plc Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 49. Dr. Reddy's Laboratories Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 50. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 51. Hetero Drugs Limited Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 52. AbbVie Inc. Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 53. Teva Pharmaceutical Industries Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 54. Novartis AG Revenue Growth Rate in Immune-mediated Necrotizing Myopathy Treatment Business (2020-2025)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS